| 1 | Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma | 4.2 | 44 | Citations (PDF) |
| 2 | Associations between early tumor shrinkage/depth of response and survival from the ARCAD database | 2.9 | 0 | Citations (PDF) |
| 3 | Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab | 0.6 | 2 | Citations (PDF) |
| 4 | Tislelizumab in advanced/metastatic esophageal squamous cell carcinoma: health-related quality of life in Asian patients | 2.1 | 4 | Citations (PDF) |
| 5 | Bleeding and Perforation Complications after Follow-Up Colonoscopies in Faecal Immunochemical Test-Based Colorectal Cancer Screening: Insights from a Retrospective Case–Control Study | 0.9 | 2 | Citations (PDF) |
| 6 | Bleeding and Perforation Complications after Follow-Up Colonoscopies in Faecal Immunochemical Test-Based Colorectal Cancer Screening: Insights from a Retrospective Case–Control Study | 0.9 | 1 | Citations (PDF) |
| 7 | Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review | 3.4 | 7 | Citations (PDF) |
| 8 | Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review | 2.6 | 2 | Citations (PDF) |
| 9 | Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database | 5.5 | 3 | Citations (PDF) |
| 10 | Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study | 2.9 | 7 | Citations (PDF) |
| 11 | 35P Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial | 9.9 | 3 | Citations (PDF) |
| 12 | Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study | 2.6 | 2 | Citations (PDF) |
| 13 | Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer | 3.9 | 1 | Citations (PDF) |
| 14 | Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer | 6.8 | 9 | Citations (PDF) |
| 15 | Salvage Surgery for Unifocal Progressive Metastatic Mismatch Repair–Deficient GI Cancer Responding to Immune Checkpoint Inhibition | 1.9 | 0 | Citations (PDF) |
| 16 | European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer | 9.5 | 24 | Citations (PDF) |
| 17 | A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAFV600E-MutantKRASWild-Type Metastatic Colorectal Cancer | 3.4 | 53 | Citations (PDF) |
| 18 | The Role of cMET in Gastric Cancer—A Review of the Literature | 3.8 | 17 | Citations (PDF) |
| 19 | Pharmacokinetic drug–drug interactions with direct anticoagulants in the management of cancer‐associated thrombosis | 2.5 | 15 | Citations (PDF) |
| 20 | Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial | 3.4 | 2 | Citations (PDF) |
| 21 | 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use | 5.1 | 32 | Citations (PDF) |
| 22 | Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality | 6.4 | 10 | Citations (PDF) |
| 23 | Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study | 2.3 | 1 | Citations (PDF) |
| 24 | Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer | 3.4 | 3 | Citations (PDF) |
| 25 | Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials | 4.6 | 13 | Citations (PDF) |
| 26 | Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology | 4.6 | 6 | Citations (PDF) |
| 27 | Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib | 5.0 | 16 | Citations (PDF) |
| 28 | Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years | 4.9 | 13 | Citations (PDF) |
| 29 | Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer | 5.3 | 37 | Citations (PDF) |
| 30 | Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials | 2.9 | 4 | Citations (PDF) |
| 31 | Prevalence of microsatellite instable and Epstein-Barr Virus-driven gastro-
esophageal cancer in a large Belgian cohort | 0.8 | 5 | Citations (PDF) |
| 32 | Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis | 4.9 | 84 | Citations (PDF) |
| 33 | Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies | 3.8 | 41 | Citations (PDF) |
| 34 | First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | 5.5 | 12 | Citations (PDF) |
| 35 | MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer | 2.3 | 125 | Citations (PDF) |
| 36 | Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 | 9.9 | 234 | Citations (PDF) |
| 37 | Pre-treatment cross-talk between the tumoural and peripheral immune system predicts response to checkpoint inhibition in advanced HCC: a single-cell study | 4.2 | 1 | Citations (PDF) |
| 38 | Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study | 6.8 | 86 | Citations (PDF) |
| 39 | Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life | 5.3 | 22 | Citations (PDF) |
| 40 | Health-related quality of life in rectal cancer: a topic more relevant now than ever | 2.9 | 0 | Citations (PDF) |
| 41 | Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer | 3.4 | 6 | Citations (PDF) |
| 42 | Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis | 3.6 | 3 | Citations (PDF) |
| 43 | Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study | 3.4 | 6 | Citations (PDF) |
| 44 | BRAFV600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database | 4.6 | 45 | Citations (PDF) |
| 45 | A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy | 0.7 | 1 | Citations (PDF) |
| 46 | Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | 34.5 | 1,612 | Citations (PDF) |
| 47 | Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study | 9.9 | 103 | Citations (PDF) |
| 48 | Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer | 4.6 | 25 | Citations (PDF) |
| 49 | Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Management of Metastatic Colorectal Cancer: SUNLIGHT Study Design | 2.3 | 43 | Citations (PDF) |
| 50 | Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study | 2.1 | 6 | Citations (PDF) |
| 51 | Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study | 5.3 | 14 | Citations (PDF) |
| 52 | Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study | 5.3 | 20 | Citations (PDF) |
| 53 | Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 | 3.4 | 15 | Citations (PDF) |
| 54 | KEYNOTE-859: a Phase III Study of Pembrolizumab Plus Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma | 2.3 | 56 | Citations (PDF) |
| 55 | Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database | 4.6 | 44 | Citations (PDF) |
| 56 | Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial | 3.4 | 142 | Citations (PDF) |
| 57 | Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 3.4 | 23 | Citations (PDF) |
| 58 | Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study | 27.4 | 64 | Citations (PDF) |
| 59 | Pulmonary Metastasectomy in Colorectal Cancer: has the randomized controlled trial brought enough reliable evidence to convince believers in metastasectomy to reconsider their oncological practice? | 1.4 | 10 | Citations (PDF) |
| 60 | 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial | 27.4 | 529 | Citations (PDF) |
| 61 | Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival 2021, 9, e003580 | | 41 | Citations (PDF) |
| 62 | Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study | 5.3 | 24 | Citations (PDF) |
| 63 | Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy | 14.3 | 18 | Citations (PDF) |
| 64 | Predicting the tumor response to chemoradiotherapy for rectal cancer: Model development and external validation using MRI radiomics | 2.0 | 81 | Citations (PDF) |
| 65 | Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 | 16.9 | 900 | Citations (PDF) |
| 66 | Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials | 9.9 | 61 | Citations (PDF) |
| 67 | Inflammation-Based Index and 68Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC | 5.1 | 39 | Citations (PDF) |
| 68 | Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
Post Hoc
Analysis of the VELOUR Trial | 6.8 | 55 | Citations (PDF) |
| 69 | Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report | 2.2 | 1 | Citations (PDF) |
| 70 | Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer | 34.5 | 2,695 | Citations (PDF) |
| 71 | Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis | 34.5 | 66 | Citations (PDF) |
| 72 | Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis | 5.3 | 52 | Citations (PDF) |
| 73 | Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer | 6.6 | 16 | Citations (PDF) |
| 74 | Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review | 3.2 | 22 | Citations (PDF) |
| 75 | Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study | 5.3 | 38 | Citations (PDF) |
| 76 | Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study | 27.4 | 1,451 | Citations (PDF) |
| 77 | Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer | 3.6 | 54 | Citations (PDF) |
| 78 | Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study | 9.9 | 55 | Citations (PDF) |
| 79 | [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients | 5.5 | 82 | Citations (PDF) |
| 80 | Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT | 1.8 | 10 | Citations (PDF) |
| 81 | DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer | 3.9 | 97 | Citations (PDF) |
| 82 | Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study | 4.9 | 40 | Citations (PDF) |
| 83 | An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial | 3.8 | 7 | Citations (PDF) |
| 84 | Characterization of Liver Metastases During Catheter-Directed Liver Interventions: A Comparison between Dual Phase Cone-Beam Computed Tomography and Conventional Contrast-Enhanced Computed Tomography | 0.4 | 2 | Citations (PDF) |
| 85 | Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumor and liver perfusion territory definition | 2.6 | 8 | Citations (PDF) |
| 86 | 197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859 | 9.9 | 2 | Citations (PDF) |
| 87 | Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies | 9.9 | 126 | Citations (PDF) |
| 88 | Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR) | 9.9 | 0 | Citations (PDF) |
| 89 | Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer | 6.6 | 11 | Citations (PDF) |
| 90 | A Phase III Open-Label Trial to Evaluate Efficacy and Safety of CPI-613 Plus Modified FOLFIRINOX (MFFX) versus FOLFIRINOX (FFX) in Patients with Metastatic Adenocarcinoma of the Pancreas | 2.3 | 88 | Citations (PDF) |
| 91 | Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses | 2.6 | 5 | Citations (PDF) |
| 92 | Encorafenib, Binimetinib, and Cetuximab in
BRAF
V600E–Mutated Colorectal Cancer | 34.5 | 1,386 | Citations (PDF) |
| 93 | Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib | 9.9 | 40 | Citations (PDF) |
| 94 | Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer | 3.4 | 49 | Citations (PDF) |
| 95 | Maximising clinical benefit with adequate patient management beyond the second line in mCRC | 5.3 | 22 | Citations (PDF) |
| 96 | Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence | 9.5 | 64 | Citations (PDF) |
| 97 | Maintenance Olaparib for Germline
BRCA
-Mutated Metastatic Pancreatic Cancer | 34.5 | 2,145 | Citations (PDF) |
| 98 | Canstem111P Trial: A Phase Iii Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine | 2.3 | 46 | Citations (PDF) |
| 99 | Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty | 5.3 | 2 | Citations (PDF) |
| 100 | Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study | 3.4 | 120 | Citations (PDF) |
| 101 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | 9.9 | 207 | Citations (PDF) |
| 102 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | 9.9 | 205 | Citations (PDF) |
| 103 | Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases | 2.8 | 114 | Citations (PDF) |
| 104 | Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study | 9.9 | 64 | Citations (PDF) |
| 105 | A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors | 6.8 | 70 | Citations (PDF) |
| 106 | Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease | 27.4 | 66 | Citations (PDF) |
| 107 | The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer | 4.9 | 88 | Citations (PDF) |
| 108 | Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study | 9.9 | 98 | Citations (PDF) |
| 109 | Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies | 2.5 | 103 | Citations (PDF) |
| 110 | Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW | 2.5 | 26 | Citations (PDF) |
| 111 | Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS) | 1.8 | 17 | Citations (PDF) |
| 112 | Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study | 9.9 | 1 | Citations (PDF) |
| 113 | Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database | 4.9 | 14 | Citations (PDF) |
| 114 | Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018 | 4.9 | 68 | Citations (PDF) |
| 115 | Association of Patient Sex With Chemotherapy-Related Toxic Effects | 14.3 | 57 | Citations (PDF) |
| 116 | Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer | 4.3 | 95 | Citations (PDF) |
| 117 | Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group | 4.9 | 34 | Citations (PDF) |
| 118 | Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 | 9.9 | 463 | Citations (PDF) |
| 119 | Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study | 9.9 | 61 | Citations (PDF) |
| 120 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | 62.1 | 1,222 | Citations (PDF) |
| 121 | Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study | 4.9 | 23 | Citations (PDF) |
| 122 | Session 2: Synchronous metastatic disease–liver first or primary first? The oncologist decides | 2.0 | 2 | Citations (PDF) |
| 123 | More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer | 0.1 | 11 | Citations (PDF) |
| 124 | Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial | 0.5 | 40 | Citations (PDF) |
| 125 | Phase 3 Trial of
177
Lu-Dotatate for Midgut Neuroendocrine Tumors | 34.5 | 3,072 | Citations (PDF) |
| 126 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials | 9.9 | 782 | Citations (PDF) |
| 127 | Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage i rectal cancer: A real standard? | 5.0 | 37 | Citations (PDF) |
| 128 | Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib | 2.6 | 12 | Citations (PDF) |
| 129 | A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification | 9.9 | 183 | Citations (PDF) |
| 130 | A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial | 9.9 | 96 | Citations (PDF) |
| 131 | Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer | 9.9 | 55 | Citations (PDF) |
| 132 | Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response | 3.6 | 41 | Citations (PDF) |
| 133 | Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients | 9.9 | 47 | Citations (PDF) |
| 134 | Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona | 4.9 | 23 | Citations (PDF) |
| 135 | Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | 27.4 | 85 | Citations (PDF) |
| 136 | External Validation of the Prognostic Nomogram (COMPASS) for Patients with Peritoneal Carcinomatosis of Colorectal Cancer | 2.3 | 20 | Citations (PDF) |
| 137 | Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial | 5.3 | 29 | Citations (PDF) |
| 138 | QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer | 5.3 | 19 | Citations (PDF) |
| 139 | Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer | 2.0 | 40 | Citations (PDF) |
| 140 | Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study | 9.9 | 124 | Citations (PDF) |
| 141 | Hepatic radiation injury mimicking metastasis in distal esophageal cancer | 1.1 | 2 | Citations (PDF) |
| 142 | Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study | 9.9 | 184 | Citations (PDF) |
| 143 | Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy | 2.6 | 17 | Citations (PDF) |
| 144 | Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer | 14.3 | 647 | Citations (PDF) |
| 145 | Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial | 4.6 | 615 | Citations (PDF) |
| 146 | Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial | 2.9 | 13 | Citations (PDF) |
| 147 | Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report | 3.8 | 8 | Citations (PDF) |
| 148 | Relevance of the stroma in pancreatic ductal adenocarcinoma and its challenges for translational research | 0.0 | 1 | Citations (PDF) |
| 149 | Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians | 3.8 | 80 | Citations (PDF) |
| 150 | FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study | 0.9 | 28 | Citations (PDF) |
| 151 | Treatment sequence of synchronously (liver) metastasized colon cancer | 2.5 | 15 | Citations (PDF) |
| 152 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | 9.9 | 3,124 | Citations (PDF) |
| 153 | Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial | 5.5 | 51 | Citations (PDF) |
| 154 | A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma | 3.6 | 7 | Citations (PDF) |
| 155 | Gastric cancer | 62.1 | 1,794 | Citations (PDF) |
| 156 | The multidisciplinary management of gastro-oesophageal junction tumours | 2.5 | 25 | Citations (PDF) |
| 157 | Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102) | 9.9 | 0 | Citations (PDF) |
| 158 | Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer | 4.9 | 75 | Citations (PDF) |
| 159 | Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma | 9.9 | 74 | Citations (PDF) |
| 160 | Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment | 2.6 | 27 | Citations (PDF) |
| 161 | Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer | 5.5 | 29 | Citations (PDF) |
| 162 | Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer | 25.1 | 73 | Citations (PDF) |
| 163 | Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development | 9.5 | 15 | Citations (PDF) |
| 164 | A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors | 6.8 | 304 | Citations (PDF) |
| 165 | A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial | 9.9 | 158 | Citations (PDF) |
| 166 | Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis | 5.5 | 142 | Citations (PDF) |
| 167 | Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | 27.4 | 318 | Citations (PDF) |
| 168 | Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus | 9.5 | 565 | Citations (PDF) |
| 169 | Pooled analysis of the surgical treatment for colorectal cancer liver metastases | 5.0 | 31 | Citations (PDF) |
| 170 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial | 4.9 | 54 | Citations (PDF) |
| 171 | Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial | 5.5 | 30 | Citations (PDF) |
| 172 | Impact of Prior Chemotherapy Use on the Efficacy of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | 0.9 | 46 | Citations (PDF) |
| 173 | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients | 9.9 | 40 | Citations (PDF) |
| 174 | Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting | 5.5 | 37 | Citations (PDF) |
| 175 | Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study | 9.9 | 112 | Citations (PDF) |
| 176 | Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial | 9.9 | 113 | Citations (PDF) |
| 177 | Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy | 3.2 | 43 | Citations (PDF) |
| 178 | Folfiri Plus Cetuximab in Patients with Liver-Limited or Non-Liver-Limited Ras Wild-Type Metastatic Disease: a Sub-Group Analysis of the Crystal Study | 9.9 | 2 | Citations (PDF) |
| 179 | Lume-Colon 1: Double-Blind, Randomised Phase III Study of Nintedanib (Bibf 1120) Plus Best Supportive Care (Bsc) Versus Placebo Plus Bsc in Patients (Pts) with Refractory Colorectal Cancer | 9.9 | 1 | Citations (PDF) |
| 180 | Adjuvant Regorafenib (Reg) in Stage Iv Colorectal Cancer (Crc) After Curative Treatment of Liver Metastases: a Phase III Randomized, Placebo (Pbo)-Controlled Trial (Coast) | 9.9 | 2 | Citations (PDF) |
| 181 | Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care | 3.4 | 72 | Citations (PDF) |
| 182 | Postgastrectomy protein-losing cytomegalovirus jejunitis in an immunocompromised patient | 0.5 | 0 | Citations (PDF) |
| 183 | Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study | 5.5 | 39 | Citations (PDF) |
| 184 | Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset | 9.9 | 103 | Citations (PDF) |
| 185 | Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type
KRAS
Metastatic Colorectal Cancer | 6.8 | 110 | Citations (PDF) |
| 186 | Treatment-related mortality with aflibercept in cancer patients | 2.0 | 1 | Citations (PDF) |
| 187 | Unmet needs and challenges in gastric cancer: The way forward | 9.5 | 163 | Citations (PDF) |
| 188 | Quality of Life in the Trastuzumab for Gastric Cancer Trial | 3.4 | 61 | Citations (PDF) |
| 189 | Hypoxia-Driven Gene Expression Is an Independent Prognostic Factor in Stage II and III Colon Cancer Patients | 6.8 | 32 | Citations (PDF) |
| 190 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | 27.4 | 2,302 | Citations (PDF) |
| 191 | Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial | 27.4 | 278 | Citations (PDF) |
| 192 | HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer | 3.4 | 565 | Citations (PDF) |
| 193 | An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer | 3.2 | 33 | Citations (PDF) |
| 194 | Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin | 4.9 | 62 | Citations (PDF) |
| 195 | Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | 34.5 | 6,236 | Citations (PDF) |
| 196 | Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay | 2.6 | 5 | Citations (PDF) |
| 197 | Prospective Comparison of Hydrogel-coated Microcoils versus Fibered Platinum Microcoils in the Prophylactic Embolization of the Gastroduodenal Artery before Yttrium-90 Radioembolization | 1.1 | 26 | Citations (PDF) |
| 198 | Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth | 8.6 | 173 | Citations (PDF) |
| 199 | Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase I study | 4.9 | 16 | Citations (PDF) |
| 200 | Role of targeted agents in metastatic colorectal cancer | 3.2 | 59 | Citations (PDF) |
| 201 | Improving outcomes in colorectal cancer: Where do we go from here? | 4.9 | 50 | Citations (PDF) |
| 202 | Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours | 4.9 | 36 | Citations (PDF) |
| 203 | Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer | 5.5 | 46 | Citations (PDF) |
| 204 | Influence of Time Delay on the Estimated Lung Shunt Fraction on 99mTc-Labeled MAA Scintigraphy for 90Y Microsphere Treatment Planning | 2.4 | 25 | Citations (PDF) |
| 205 | Persisting anorectal dysfunction after rectal cancer surgery | 2.0 | 14 | Citations (PDF) |
| 206 | Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer | 5.5 | 34 | Citations (PDF) |
| 207 | HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? | 9.9 | 70 | Citations (PDF) |
| 208 | Management of advanced gastric cancer | 2.3 | 69 | Citations (PDF) |
| 209 | Value of Diffusion-Weighted Magnetic Resonance Imaging for Prediction and Early Assessment of Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: Preliminary Results | 1.5 | 188 | Citations (PDF) |
| 210 | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials | 4.9 | 540 | Citations (PDF) |
| 211 | Impact of Interval between Neoadjuvant Chemoradiotherapy and TME for Locally Advanced Rectal Cancer on Pathologic Response and Oncologic Outcome | 2.3 | 136 | Citations (PDF) |
| 212 | Progress in the management of chemorefractory colorectal cancer | 0.5 | 0 | Citations (PDF) |
| 213 | Chemotherapy Plus Cetuximab in Patients with Colorectal Metastases Grouped by Site: A Pooled Analysis of the Crystal and OPUS Studies | 9.9 | 0 | Citations (PDF) |
| 214 | Sensitivity Analyses of Progression-Free Survival (PFS) of Aflibercept-Folfiri Versus Placebo-Folfiri in Metastatic Colorectal Cancer (MCRC): Results from the Velour Study | 9.9 | 1 | Citations (PDF) |
| 215 | Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies | 9.9 | 1 | Citations (PDF) |
| 216 | Early Tumor Shrinkage and Clinical Outcome in Metastatic Colorectal Cancer: Analysis of Predictive Utility in the CRYSTAL and OPUS Studies | 9.9 | 1 | Citations (PDF) |
| 217 | First-Line Chemotherapy Plus Cetuximab in Patients Grouped According to Prognostic Risk Factors: Analysis of the Crystal and OPUS Studies | 9.9 | 0 | Citations (PDF) |
| 218 | TP, TS AND DPD as Potential Predictors of Outcome Following Capecitabine Plus Oxaliplatin (XELOX) vs. Bolus 5-Fluorouracil/Leucovorin (5-FU/LV) as Adjuvant Therapy for Stage III Colon Cancer: Updated Biomarker Findings from Study NO16968 (XELOXA) | 9.9 | 0 | Citations (PDF) |
| 219 | Axe Beam: Encouraging Early Results of a Neo-Adjuvant Bevacizumab, Capecitabine +/- Oxaliplatin and Radiation Multimodality Regimen for Locally Advanced Rectal Cancer | 9.9 | 0 | Citations (PDF) |
| 220 | What to Choose as Radical Local Treatment for Lung Metastases from Colo-Rectal Cancer: Surgery, Radiofrequency Ablation or Stereotactic Radiotherapy? | 9.9 | 1 | Citations (PDF) |
| 221 | Quality of Life Analysis in Patients with Kras Wild-Type Metastatic Colorectal Cancer Treated with First-Line Folfiri Plus Cetuximab | 9.9 | 0 | Citations (PDF) |
| 222 | Aflibercept/Folfiri (AF) VS Placebo/Folfiri (PF) In Metastatic Colorectal Cancer (MCRC): Post-Hoc Analysis of Survival Excluding Adjuvant (ADJ)-Only Patients in the Velour Trial | 9.9 | 0 | Citations (PDF) |
| 223 | Adjuvant Folfox4 Plus or Minus Cetuximab (CMAB) in Patients (PTS) with Kras Mutant (MKRAS) Resected Stage III Colon Cancer (CC). Results from the PETACC8 Intergroup Trial | 9.9 | 8 | Citations (PDF) |
| 224 | Minimally invasive liver surgery for metastases from colorectal cancer: oncologic outcome and prognostic factors | 2.3 | 16 | Citations (PDF) |
| 225 | The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study | 2.3 | 102 | Citations (PDF) |
| 226 | The Need for a New Fluoropyrimidine in Advanced Gastric Cancer Treatment | 0.1 | 0 | Citations (PDF) |
| 227 | The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 | 9.9 | 115 | Citations (PDF) |
| 228 | Quality assurance in colonoscopy for colorectal cancer diagnosis | 0.9 | 11 | Citations (PDF) |
| 229 | A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer | 4.9 | 453 | Citations (PDF) |
| 230 | Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC) | 4.9 | 11 | Citations (PDF) |
| 231 | European initiatives in colorectal cancer screening | 1.3 | 8 | Citations (PDF) |
| 232 | Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia | 3.2 | 47 | Citations (PDF) |
| 233 | Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents | 3.2 | 52 | Citations (PDF) |
| 234 | Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients | 9.9 | 83 | Citations (PDF) |
| 235 | Current Treatment Standards in Metastatic Colorectal Cancer — The Role of Anti-epidermal Growth Factor Antibodies | 0.1 | 0 | Citations (PDF) |
| 236 | Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model | 3.6 | 7 | Citations (PDF) |
| 237 | Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of anti‐VEGF and anti‐EGFR antibodies | 1.5 | 8 | Citations (PDF) |
| 238 | New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer | 6.8 | 71 | Citations (PDF) |
| 239 | Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy | 1.8 | 3 | Citations (PDF) |
| 240 | MALIGNANT INVOLVEMENT OF THE KNEE SYNOVIUM IN A PATIENT WITH METASTASTIC OESOPHAGEAL ADENOCARCINOMA | 1.4 | 5 | Citations (PDF) |
| 241 | The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer | 1.8 | 129 | Citations (PDF) |
| 242 | The Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases | 2.6 | 41 | Citations (PDF) |
| 243 | EORTC Elderly Task Force experts’ opinion for the treatment of colon cancer in older patients | 9.5 | 67 | Citations (PDF) |
| 244 | Improved first-line chemotherapy: a better chance for surgery? | 27.4 | 3 | Citations (PDF) |
| 245 | Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development | 45.8 | 140 | Citations (PDF) |
| 246 | Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation | 2.3 | 23 | Citations (PDF) |
| 247 | Carcinoid heart disease: Case and literature review | 1.3 | 16 | Citations (PDF) |
| 248 | Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) | 9.9 | 77 | Citations (PDF) |
| 249 | Tissue Biomarker Development in a Multicentre Trial Context: a Feasibility Study on the PETACC3 Stage II and III Colon Cancer Adjuvant Treatment Trial | 6.8 | 30 | Citations (PDF) |
| 250 | Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy | 4.0 | 136 | Citations (PDF) |
| 251 | Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study | 2.1 | 23 | Citations (PDF) |
| 252 | Gastric cancer | 5.0 | 361 | Citations (PDF) |
| 253 | Acute and long-term gastrointestinal consequences of chemotherapy | 2.7 | 70 | Citations (PDF) |
| 254 | Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial | 5.5 | 160 | Citations (PDF) |
| 255 | Implications for KRAS status and EGFR-targeted therapies in metastatic CRC | 70.7 | 426 | Citations (PDF) |
| 256 | Double blind randomized phase II study with radiation+5-fluorouracil±celecoxib for resectable rectal cancer | 2.0 | 39 | Citations (PDF) |
| 257 | 6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial | 0.5 | 6 | Citations (PDF) |
| 258 | Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer | 2.5 | 161 | Citations (PDF) |
| 259 | The role of chemotherapy in biliary tract carcinoma | 0.3 | 30 | Citations (PDF) |
| 260 | Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group | 4.9 | 93 | Citations (PDF) |
| 261 | To the Editor | 16.9 | 4 | Citations (PDF) |
| 262 | A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients | 9.9 | 31 | Citations (PDF) |
| 263 | Computed Tomographic Colonography | 1.0 | 4 | Citations (PDF) |
| 264 | Long-term Survival and Metastatic Pattern of Pancreatic and Periampullary Cancer After Adjuvant Chemoradiation or Observation | 4.6 | 305 | Citations (PDF) |
| 265 | COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN COMPARED WITH CURRENT CARE IN METASTATIC COLORECTAL CANCER AFTER FAILURE ON IRINOTECAN – A BELGIAN ANALYSIS | 1.4 | 19 | Citations (PDF) |
| 266 | Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago–gastric junction and the stomach | 4.9 | 186 | Citations (PDF) |
| 267 | Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study | 27.4 | 216 | Citations (PDF) |
| 268 | The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer | 2.7 | 36 | Citations (PDF) |
| 269 | Perineal Colostomy with Appendicostomy as an Alternative for an Abdominal Colostomy: Symptoms, Functional Status, Quality of Life, and Perceived Health | 1.7 | 21 | Citations (PDF) |
| 270 | Novel cytotoxic regimens in gastric cancer | 0.5 | 4 | Citations (PDF) |
| 271 | Does a patient’s self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? | 4.9 | 143 | Citations (PDF) |
| 272 | Towards a pan-European consensus on the treatment of patients with colorectal liver metastases | 4.9 | 530 | Citations (PDF) |
| 273 | A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane | 2.5 | 34 | Citations (PDF) |
| 274 | Germline Mutations of the hMLH1 and hMSH2 Mismatch Repair Genes in Belgian Hereditary Nonpolyposis Colon Cancer (HNPCC) Patients | 1.4 | 14 | Citations (PDF) |
| 275 | Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab | 3.2 | 3 | Citations (PDF) |
| 276 | Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer | 3.4 | 52 | Citations (PDF) |
| 277 | Gastric cancer | 5.0 | 81 | Citations (PDF) |
| 278 | Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study | 5.5 | 33 | Citations (PDF) |
| 279 | Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment | 1.9 | 10 | Citations (PDF) |
| 280 | Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma | 16.9 | 214 | Citations (PDF) |
| 281 | Adjuvant chemotherapy for stage III colon cancer in 2005: where are we now? | 0.5 | 1 | Citations (PDF) |
| 282 | A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial | 4.9 | 127 | Citations (PDF) |
| 283 | Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer | 0.9 | 6 | Citations (PDF) |
| 284 | The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes | 3.4 | 59 | Citations (PDF) |
| 285 | Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials | 9.9 | 112 | Citations (PDF) |
| 286 | New approaches for the treatment of colorectal cancer in the adjuvant setting | 0.5 | 1 | Citations (PDF) |
| 287 | Docetaxel in gastric cancer | 0.5 | 4 | Citations (PDF) |
| 288 | What have we learned and where are we going in the treatment of colorectal and gastric cancer? | 0.5 | 0 | Citations (PDF) |
| 289 | Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? | 2.0 | 123 | Citations (PDF) |
| 290 | Treatment of a Metastasis of a Rectal Carcinoma in the Greater Trochanter with the AO/ASIF Proximal Femoral Nail. A case report | 1.1 | 5 | Citations (PDF) |
| 291 | Systemic treatment of pancreatic cancer | 1.3 | 40 | Citations (PDF) |
| 292 | The role of oxaliplatin in the management of upper gastrointestinal tract malignancies | 2.0 | 3 | Citations (PDF) |
| 293 | Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy | 9.9 | 43 | Citations (PDF) |
| 294 | Current treatments and future perspectives in colorectal and gastric cancer | 9.9 | 41 | Citations (PDF) |
| 295 | Effects of preoperative chemoradiotherapy on postsurgical morbidity and mortality in cT3–4 +/− cM1lymph cancer of the oesophagus and gastro-oesophageal junction | 1.4 | 25 | Citations (PDF) |
| 296 | UFT/LV: a novel concept in the chemotherapy of metastatic colorectal cancer | 1.3 | 0 | Citations (PDF) |
| 297 | Stool Tagging Applied in Thin-slice Multidetector Computed Tomography Colonography | 1.0 | 57 | Citations (PDF) |
| 298 | UFT and leucovorin in metastatic colorectal cancer: clinical insights | 1.3 | 0 | Citations (PDF) |
| 299 | UFT/LV: future directions | 1.3 | 0 | Citations (PDF) |
| 300 | Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil | 9.9 | 141 | Citations (PDF) |
| 301 | Whole-body PET with FDG for the diagnosis of recurrent gastric cancer | 5.5 | 157 | Citations (PDF) |
| 302 | The role of chemotherapy in the current treatment of gastric cancer | 3.4 | 35 | Citations (PDF) |
| 303 | Patient acceptance for CT colonography: what is the real issue? | 3.6 | 105 | Citations (PDF) |
| 304 | Molecular and genetic defects in colorectal tumorigenesis | 2.7 | 26 | Citations (PDF) |
| 305 | The treatment of advanced colorectal cancer: where are we now and where do we go? | 2.7 | 21 | Citations (PDF) |
| 306 | Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases | 0.9 | 71 | Citations (PDF) |
| 307 | Recent advances in the management of colorectal cancer | 4.9 | 12 | Citations (PDF) |
| 308 | Toxicity of Irinotecan in Patients with Colorectal Cancer | 34.5 | 47 | Citations (PDF) |
| 309 | The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer | 2.6 | 170 | Citations (PDF) |
| 310 | Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study | 16.9 | 312 | Citations (PDF) |
| 311 | New directions in the treatment of colorectal cancer | 4.9 | 79 | Citations (PDF) |
| 312 | 10.1016/j.ejces.2007.11.002 | 0.0 | 0 | Citations (PDF) |
| 313 | Additional Value of Whole-Body Positron Emission Tomography With Fluorine-18-2-Fluoro-2-deoxy-d-glucose in Recurrent Colorectal Cancer | 16.9 | 226 | Citations (PDF) |
| 314 | Screening applications for MRI in the detection of upper abdominal disease: comparative study of non-contrast-enhanced single-shot MRI and contrast-enhanced helical CT | 3.6 | 9 | Citations (PDF) |
| 315 | Transcatheter embolization of hepatic arteriovenous fistulas in Rendu-Osler-Weber disease: a case report and review of the literature | 3.6 | 27 | Citations (PDF) |
| 316 | Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU | 4.9 | 38 | Citations (PDF) |
| 317 | Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure | 1.3 | 3 | Citations (PDF) |
| 318 | Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies | 1.3 | 8 | Citations (PDF) |
| 319 | Developments in fluoropyrimidine therapy for gastrointestinal cancer | 2.1 | 10 | Citations (PDF) |
| 320 | Raltitrexed (Tomudex™) | 3.9 | 7 | Citations (PDF) |
| 321 | Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying | 16.8 | 103 | Citations (PDF) |
| 322 | Intestinal metaplasia in gastric malignancy | 1.3 | 9 | Citations (PDF) |
| 323 | Primary liver tumour of intermediate (hepatocyte—bile duct cell) phenotype: a progenitor cell tumour? | 0.0 | 75 | Citations (PDF) |
| 324 | Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration | 1.4 | 33 | Citations (PDF) |
| 325 | Corrigenda | 9.9 | 0 | Citations (PDF) |
| 326 | Future developments with ??Tomudex?? (raltitrexed) | 1.3 | 11 | Citations (PDF) |
| 327 | Surgery for gastric remnant carcinoma following Billroth II gastrectomy | 0.9 | 12 | Citations (PDF) |
| 328 | Corrigenda | 9.9 | 0 | Citations (PDF) |
| 329 | A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer | 4.9 | 8 | Citations (PDF) |
| 330 | Pharmacologic Therapy of Arteriovenous Malformations | 1.7 | 24 | Citations (PDF) |
| 331 | Final results of a randomised trial comparing ‘Tomudex’® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer | 9.9 | 188 | Citations (PDF) |
| 332 | Reporting on the results of cancer treatment in patients with metastatic liver disease: Proposal of symmetric size-dependent CT-criteria for response | 9.9 | 5 | Citations (PDF) |
| 333 | ‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia | 4.9 | 126 | Citations (PDF) |
| 334 | Long-term effect of hormonal therapy for bleeding gastrointestinal vascular malformations | 1.3 | 21 | Citations (PDF) |
| 335 | Visualization and characterization of gastric contractions using a radionuclide technique | 3.2 | 22 | Citations (PDF) |
| 336 | Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone | 62.1 | 282 | Citations (PDF) |
| 337 | Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration | 4.2 | 80 | Citations (PDF) |
| 338 | Observation of the propagation direction of human electrogastric activity from cutaneous recordings | 2.3 | 44 | Citations (PDF) |
| 339 | Estrogen-Progesterone Treatment of Osier-Weber-Rendu Disease | 2.3 | 45 | Citations (PDF) |
| 340 | Lymphocytic Meningitis: A Review Of The Literature | 1.4 | 2 | Citations (PDF) |
| 341 | Multiple Brain Abscesses Caused by Torulopsis glabrata in an Immunocompromised Patient/Durch Torulopsis glabrata hervorgerufene Hirnabszesse bei einem immungeschwächten Patienten | 3.2 | 12 | Citations (PDF) |
| 342 | Association between neutropenia and efficacy in patients with refractory mCRC receiving trifluridine/tipiracil + bevacizumab: post hoc analysis of the SUNLIGHT trial | 0.6 | 2 | Citations (PDF) |
| 343 | Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study | 4.9 | 0 | Citations (PDF) |
| 344 | Impact of
RAS
/
BRAF
V600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair–Deficient/Microsatellite Instability Colorectal Cancers | 6.8 | 1 | Citations (PDF) |
| 345 | Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial | 4.5 | 2 | Citations (PDF) |
| 346 | CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma | 3.8 | 3 | Citations (PDF) |
